ClinicalTrials.gg
CompletedNCT01068158LICE OUTUpdated Apr 6, 2012Results posted

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

A Phase 3 interventional study of 0.5% Ivermectin Cream and Placebo control in Head Lice, sponsored by Topaz Pharmaceuticals Inc. Completed at 7 sites in United States. Open to participants aged 5 Months and older. Per ClinicalTrials.gov, last updated 2012-04-06.

Sponsored by Topaz Pharmaceuticals Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
371
Allocation
Randomized
Ages
5 Months and older
Sex
All
01

Study summary

The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.

02

Conditions studied

  • Head Lice

Keywords

  • Head lice infestation
  • Pediculus humanus capitis
03

In context

Lead sponsor

Topaz Pharmaceuticals Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Index subjects must have an active head lice infestation defined as: At least 3 live lice (adults and/or nymphs) present on the scalp and/or hair, as determined by a trained evaluator. The index subject must be the youngest family member presenting with at least 3 live lice. After the index subject has been identified, additional infested household members (see b below) will be enrolled.
  • Household subjects must have an active head lice infestation defined as: At least 1 live louse (adult and/or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self-assess as being lice free).
  • Subject is male or female.
  • Subject is at least 6 months of age at time of enrollment.
  • Subject is in good general health based on medical history.
  • Each subject must have an appropriately signed agreement. A caregiver must sign an Informed Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form.
  • The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, according to the criteria b (above), they must be willing and able to participate in the study. No more than one working male per household may be excluded from evaluation if he is assessed as being lice free by himself or the caregiver and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility; otherwise the entire household will be excluded from study participation.
  • Subject and/or their caregiver must be physically able and willing to apply the test article.
  • Subject agrees not to use any other form of lice treatments (commercial, community-anecdotal, or mechanical/manual) while participating in the study.
  • Following application and rinsing of the test article, subject agrees not to shampoo, wash, or rinse their hair or scalp until the 24-hour post-treatment evaluation has been completed.
  • Subject agrees to not cut or chemically treat their hair while participating in the study.
  • Subject agrees to follow all study instructions.
  • Female subjects of (including a female caregiver even if she is not being treated) must be willing to have a urine pregnancy test.
  • In the event of a subject judged to be incapable of self-treating, the household must have a caregiver willing to apply the treatment at home.

Exclusion criteria

Exclusion Criteria:

  • History of irritation or sensitivity to ivermectin or the cream components, pediculicides or hair care products.
  • Presentation at the treatment site with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or sponsor, will interfere with safety and/or efficacy evaluations.
  • Presentation at the treatment site with eczema or atopic dermatitis.
  • Treatment for head lice (over-the-counter [OTC], home remedy and/or Prescription) in the last 7 days.
  • Any condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol.
  • Is receiving any other treatment which, in the opinion of the investigator or study monitor, may interfere with the study results.
  • Females (including caregivers who come in contact with the product) who are pregnant, nursing or planning a pregnancy. (NOTE: female caregivers and all enrolled females of must have a negative urine pregnancy test prior to treatment). If a household has a pregnant female who has an active case of lice, the entire household is excluded from participation. If this pregnant household member does not have an active infestation, this individual must NOT be the caregiver (one who provides treatment to other household members).
  • Is of child-bearing potential and unwilling to use an adequate method of for the duration of the study. Adequate methods of contraception include: abstinence, vasectomized partner, oral birth control pills, birth control injections or patches, intrauterine device, condoms with a spermicidal jelly or a diaphragm with spermicidal jelly, surgical sterilization.
  • Participation in a previous investigational drug study within the past 30 days.
  • Prior participation in any ivermectin trials.
  • Does not understand the requirements for study participation and/or may likely exhibit poor compliance, in the opinion of the investigator.
  • Does not have a known household affiliation with their household members (i.e., do not stay in one household consistently, sleeping at one place several nights and then at another place or location). Household is defined as living in a shared area or space (for example the same house or apartment unit).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
371 participants (actual)

Study arms

  • Experimental
    0.5% Ivermectin Cream

    Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1

    Drug: 0.5% Ivermectin Cream

  • Placebo comparator
    Vehicle control

    Up to 4 ounces of topical control applied to hair and scalp on day 1.

    Drug: Placebo control

Interventions

  • Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.

  • DrugPlacebo control

    up to 4 ounces of topical vehicle control to head and scalp on day 1.

06

What researchers measure

Primary outcomes

  1. Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

    Treatment success, defined as absence of live lice, was assessed in index subjects, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.

    Time frame: Day 2 up to Day 15 post-application

  2. Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

    Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.

    Time frame: Day 2 up to Day 15 post-application

Secondary outcomes

  1. Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

    Adverse events were defined and classified as follows: 'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention.

    Time frame: Day 2 up to Day 15 post-application

  2. Summary of the Reported Skin/Scalp Irritation Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

    Severe skin/scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.

    Time frame: Day 2 up to Day 15 post-application

07

Results

Posted Apr 4, 2012

Participant flow

Participants were enrolled and treated from 4 March 2010 to 17 June 2010 in 8 US clinical centers.

Participant flow — Overall Study
Milestone0.5% IvermectinVehicle Control
Started169202
Completed161198
Not completed84
Withdrew: Withdrawal by subject12
Withdrew: Lost to follow-up70
Withdrew: Protocol violation02

Outcome measures

PrimaryPercentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

Treatment success, defined as absence of live lice, was assessed in index subjects, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.

Time frame:
Day 2 up to Day 15 post-application
Reported as:
Number · Percent of Participants
Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Percent of Participants0.5% IvermectinVehicle Control
Day 15 (LOCF Imputation)7119 (0 to 0)
Day 15 (Treatment Failure Imputation)6918 (0 to 0)
PrimaryPercentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.

Time frame:
Day 2 up to Day 15 post-application
Reported as:
Number · Percent of Participants
Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Percent of Participants0.5% IvermectinVehicle Control
Day 15 (LOCF Imputation)7823 (0 to 0)
Day 15 (Treatment Failure Imputation)7221 (0 to 0)
SecondaryNumber of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

Adverse events were defined and classified as follows: 'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention.

Time frame:
Day 2 up to Day 15 post-application
Reported as:
Number · Participants
Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Participants0.5% IvermectinVehicle Control
Any Conjunctivitis10 (0 to 0)
Severe Conjunctivitis00 (0 to 0)
Any Ocular Hyperemia11 (0 to 0)
Severe Ocular Hyperemia00 (0 to 0)
Any Toothache10 (0 to 0)
Severe Toothache00 (0 to 0)
Any Vomiting01 (0 to 0)
Severe Vomiting00 (0 to 0)
Any Pyrexia01 (0 to 0)
Severe Pyrexia00 (0 to 0)
Any Otitis Media01 (0 to 0)
Severe Otitis Media00 (0 to 0)
Any Excoriation11 (0 to 0)
Severe Excoriation00 (0 to 0)
Any Injury01 (0 to 0)
Severe Injury00 (0 to 0)
Any Scratch01 (0 to 0)
Severe Scratch00 (0 to 0)
Any Musculoskeletal Pain01 (0 to 0)
Severe Musculoskeletal Pain00 (0 to 0)
Any Pain in Extremity01 (0 to 0)
Severe Pain in Extremity00 (0 to 0)
Any Cough10 (0 to 0)
Severe Cough00 (0 to 0)
Any Dandruff10 (0 to 0)
Severe Dandruff00 (0 to 0)
Any Dry Skin10 (0 to 0)
Severe Dry Skin00 (0 to 0)
Any Erythema23 (0 to 0)
Severe Erythema00 (0 to 0)
Any Pruritus02 (0 to 0)
Severe Pruritus00 (0 to 0)
SecondarySummary of the Reported Skin/Scalp Irritation Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

Severe skin/scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.

Time frame:
Day 2 up to Day 15 post-application
Reported as:
Number · Participants
Summary of the Reported Skin/Scalp Irritation Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Participants0.5% IvermectinVehicle Control
Any Pruritus Day 1 (Pre-treatment; N = 169, 202)124147 (0 to 0)
Severe Pruritus Day 1 (Pre-treatment; N= 169, 202)128 (0 to 0)
Any Pruritus Day 2 (N = 166, 200)55104 (0 to 0)
Severe Pruritus Day 2 (N = 166, 200)12 (0 to 0)
Any Pruritus Day 8 (N = 148, 58)1914 (0 to 0)
Severe Pruritus Day 8 (N = 148, 58)00 (0 to 0)
Any Pruritus Day 15 (N = 142, 53)138 (0 to 0)
Severe Pruritus Day 15 (N = 142, 53)00 (0 to 0)
Erythema Day 1 (Pre-treatment; N = 169, 202)4553 (0 to 0)
Severe Erythema Day 1 (Pre-treatment; N= 169, 202)00 (0 to 0)
Any Erythema Day 2 (N = 166, 200)3141 (0 to 0)
Severe Erythema Day 2 (N = 166, 200)00 (0 to 0)
Any Erythema Day 8 (N = 148, 58)81 (0 to 0)
Severe Erythema Day 8 (N = 148, 58)00 (0 to 0)
Any Erythema Day 15 (N = 142, 53)40 (0 to 0)
Severe Erythema Day 15 (N = 142, 53)00 (0 to 0)
Any Excoriation Day 1 (Pre-treatment; N= 169, 202)4246 (0 to 0)
Severe Excoriation Day 1 (Pre-treatment N=169, 20201 (0 to 0)
Any Excoriation Day 2 (N = 166, 200)3646 (0 to 0)
Severe Excoriation Day 2 (N = 166, 200)01 (0 to 0)
Any Excoriation Day 8 (N = 148, 58)135 (0 to 0)
Severe Excoriation Day 8 (N = 148, 58)00 (0 to 0)
Any Excoriation Day 15 (N = 142, 53)54
Severe Excoriation Day 15 (N = 142, 53)00
Any Pyoderma Day 1 (Pre-treatment; N= 169, 202)32
Severe Pyoderma Day 1 (Pre-treatment; N= 169, 202)00
Any Pyoderma Day 2 (N = 166, 200)32
Severe Pyoderma Day 2 (N = 166, 200)00
Any Pyoderma Day 8 (N = 148, 58)11
Severe Pyoderma Day 8 (N = 148, 58)00
Any Pyoderma Day 15 (N = 142, 53)21
Severe Pyoderma Day 15 (N = 142, 53)00

Adverse events

Collected over Adverse event data were collected from the day of application (Day 1) through Day 28 post-application.. Non-serious events are listed at a 5.00% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.5% Ivermectin—0/169 (0%)0/169 (0%)
Vehicle Control—0/202 (0%)0/202 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)0.5% IvermectinVehicle ControlTotal
<=18 years126150276
Between 18 and 65 years425294
>=65 years101
Age Continuous
Age Continuous(Years)0.5% IvermectinVehicle ControlTotal
Mean14.37 ± 13.3315.19 ± 13.8514.82 ± 13.60
Sex: Female, Male
Sex: Female, Male(Participants)0.5% IvermectinVehicle ControlTotal
Female136151287
Male335184
Region of Enrollment
Region of Enrollment(Participants)0.5% IvermectinVehicle ControlTotal
United States169202371
08

Study locations

7 sites
  • Arkansas Pediatric Clinic
    Little Rock, Arkansas 72205, United States
  • Lice Cleanique, LLC
    Delray Beach, Florida 33484, United States
  • Hill Top Research
    St Petersburg, Florida 33710, United States
  • Lovelace Scientific Resources, Inc.
    Albuquerque, New Mexico 87108, United States
  • Haywood Pediatric and Adolescent Medicine Group, PA
    Clyde, North Carolina 28721, United States
  • LSRN
    Nashville, Tennessee 37206, United States
  • Northeast Houston Pediatric Clinic
    Houston, Texas 77015, United States
09

References and documents

Publications

  • Pariser DM, Meinking TL, Bell M, Ryan WG. Topical 0.5% ivermectin lotion for treatment of head lice. N Engl J Med. 2012 Nov 1;367(18):1687-93. doi: 10.1056/NEJMoa1200107. PubMed 23113480 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 10 months after primary completion. A results delay was requested in Mar 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2010
First posted
Feb 12, 2010
Start
Mar 2010
Primary completionActual
Jun 2010
CompletionActual
Jul 2010
Results delay requested
Mar 15, 2011
Results first posted
Apr 4, 2012
Last update
Apr 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01068158
Lead sponsor
Topaz Pharmaceuticals Inc
Responsible party
Sponsor
First posted
Feb 12, 2010
Start date
Mar 2010
Primary completion
Jun 2010
Completion
Jul 2010
Results posted
Apr 4, 2012
Last update
Apr 6, 2012

Study contacts

Medical Director
study chair · Sanofi Topaz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion